Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
IHS Leaders Tie Cybersecurity Directly to Patient Care
At the 2026 Splunk GovSummit, Indian Health Service leaders declared cybersecurity a core component of patient care. Serving 2.7 million patients across 37 states, IHS ties security to clinical continuity, emphasizing real‑time monitoring and resilience in remote and urban facilities. The agency is adopting AI to augment both security analysts and clinicians while investing heavily in staff training. Culture, flexibility, and a mission‑first mindset underpin the agency’s strategy, offering a model for other health organizations.
Scaling Cheap In‑Vivo Causal Testing for Age‑Related Diseases
AI has made hypothesis generation in bio cheap. Anyone can get an answer to ‘could this play a role in my disease’, but how do we go from ‘could’ to ‘does’? The scarce resource now is causal evidence to test hypotheses...
Semaglutide NAION Risk Higher than Risk with SGLT2 Inhibitors
A VA‑based study published in JAMA Ophthalmology found that patients with type 2 diabetes taking semaglutide experienced more than double the risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with those on SGLT2 inhibitors. The analysis covered 102,361 veterans, with...
Policy Watch: FDA Moves to Implement Trump Order on Psychedelic Drugs
President Trump’s recent executive order tasked the FDA and ARPA‑H with accelerating psychedelic research. In response, the FDA issued Commissioner’s National Priority Vouchers to three firms—Compass Pathways, Transcend Therapeutics and the Usona Institute—fast‑tracking review of psilocybin and methylone candidates for...
STAT+: FDA to Speed up Review of Three Psychedelics as Mental Health Treatments
The FDA announced it will grant priority‑review vouchers to accelerate the evaluation of three psychedelic therapies—Compass Pathways’ psilocybin for treatment‑resistant depression, Usona Institute’s psilocybin for major depressive disorder, and Transcend Therapeutics’ MDMA‑like compound for PTSD. The move is part of...
Increasing Home Care Capabilities to Decrease Hospitalizations
Hospitals are shifting more high‑acuity patients to the post‑acute and home‑care setting to expand capacity. At Becker’s 16th Annual Meeting, leaders from Tampa General, PocketRN and Homewatch CareGivers highlighted how home care, family support and technology can prevent readmissions. Tampa...
How Supplier Collaboration Drives Medical Device Innovation and Accelerates Time to Market
Velosity argues that early collaboration with contract manufacturers is essential for medical‑device OEMs to innovate and accelerate time‑to‑market. By involving manufacturers from design‑for‑manufacturability through scalable planning, companies avoid costly redesigns and gain expertise in quality, regulatory and supply‑chain risk. Velosity’s...
Canadian Life Sciences Is at a “Generational Moment,” But Experts Disagree on Its Future
Canadian life sciences, contributing roughly 2% of GDP, is at a pivotal juncture as federal and provincial governments roll out new support mechanisms. BIOTECanada highlighted a federal task force, a Life Sciences Fund and BDC Capital’s $150 million CAD (~$110 million USD)...
Outdated Screening Policy Ignoring Pancreatic Cancer Racial Disparities
The third leading cause of cancer death in America has a D-rated screening recommendation. That is the official position: do not screen. Anyone. Ever. Pancreatic cancer kills 40,000 to 50,000 Americans every year. The five-year survival rate is just over...
Male Cannabis Use Lowers Fertility, Raises Miscarriage Risk
A week ago, I featured a guest who described studies and clinical data, revealing that cannabis use by men can reduce fertility and increase miscarriage. Strong reactions on both sides about that. Note: spermatogenesis follows about a 90 day cycle...
Genomic Tool Untangles How Microbes Spread—Even when They Look Almost Identical
Researchers unveiled TRACS, a new genomic algorithm that pinpoints how microbes spread by detecting minute genetic differences. Published in Nature Microbiology, the tool successfully mapped transmission of SARS‑CoV‑2, Streptococcus pneumoniae, and Plasmodium falciparum across diverse cohorts. By distinguishing recent direct...
Readout LOUD Interview Explores Kelonia and Eli Lilly
Our Readout LOUD interview with @BRobertsVC about Kelonia and $LLY in print form. https://t.co/DsfGxwcvS3 via @statnews
‘We Want to Be Known as Your Best Partner’: UnitedHealthcare Leaders Talk Provider Tensions, Prior Auth Cuts
UnitedHealthcare's commercial unit announced further cuts to prior authorization requirements, building on a 20% reduction already achieved and targeting an additional 30% as part of its CMS‑aligned commitment. The company highlighted a 40% increase in gold‑carded provider groups, noting that...
Medicare Advantage Buyers Beware: The Rules for Selling Plans Are Changin...
The Centers for Medicare & Medicaid Services (CMS) is easing marketing rules for Medicare Advantage (MA) plans, allowing brokers and agents to promote private‑insurance alternatives with fewer disclosure constraints. The change comes as MA enrollment already covers roughly 51% of...
:max_bytes(150000):strip_icc():format(jpeg)/xanax-withdrawal-symptoms-timeline-and-treatment-4685921_V2-8fa2660abc484c10a4cab7c2fa3029a3.png)
How Long Does Xanax Withdrawal Last?
Xanax (alprazolam) is widely prescribed for anxiety and insomnia, but even short‑term use can create physical dependence. Withdrawal symptoms can begin within 8‑12 hours, peak between days three and five, and may persist for weeks, with a protracted phase lasting...
St. Jude CFO to Step Down for West Virginia Role
Pat Keel, the chief financial officer of St. Jude Children’s Research Hospital, announced she will leave the Memphis‑based nonprofit after more than a decade to assume a new executive position in West Virginia. Keel joined St. Jude in February 2016...
Flash Drives and Funny Numbers: What Elevance Health’s Earnings Really Reveal
Elevance Health posted Q1 adjusted earnings of $12.58 per share, surpassing analysts' forecasts and lifted its full‑year adjusted EPS outlook. The company simultaneously disclosed a $935 million charge representing its best estimate of potential Medicare Advantage overpayments tied to seven years...
Hawke’s Bay Hospital ED to Get Peer Mental Health Support Workers
New Zealand’s Mental Health Minister Matt Doocey announced a $61.6 million (≈ US$37 million) investment to place peer mental‑health support workers in emergency departments, starting with Hawke’s Bay, Whangārei and Hutt Valley. The program expands a model already operating in eight hospitals to...
Providence Launches 12 Epic AI Tools
Providence, a 51‑hospital system, upgraded its Epic electronic health record in April and launched 12 AI‑driven tools across inpatient, ambulatory and revenue‑cycle workflows. The suite includes an AI Text Assistant that converts clinical notes into patient‑friendly language, Inpatient Insights that...
Protecting Innovation for Psychedelic Therapies Fast-Tracked Under New Executive Order
President Donald J. Trump signed an executive order that fast‑tracks FDA approval for breakthrough psychedelic therapies targeting serious mental illness. The order creates a Commissioner’s National Priority Voucher program, establishes pre‑approval patient access pathways, and earmarks $50 million in federal funding...
HCA Still Expects up to $900M Hit From ACA Headwinds
HCA Healthcare reaffirmed its 2026 outlook, still expecting a $600 million‑$900 million EBITDA headwind from changes to the ACA exchange, including the loss of enhanced subsidies. The first‑quarter results showed a $150 million EBITDA drag as exchange‑related admissions fell roughly 15% year‑over‑year, while...
DOJ Asks For Stay Pending Appeal In ACIP Court Case
The U.S. Department of Justice has asked a federal appeals court to pause all further action in a lawsuit filed by medical organizations challenging recent changes to the Advisory Committee on Immunization Practices (ACIP). The request seeks a stay pending...
EU Biotech Act: The European Commission’s Landmark Proposal to Strengthen Biotechnology in Europe
On December 2025 the European Commission unveiled the European Biotech Act, a sweeping proposal aimed at cementing the EU’s position as a global biotech leader against the United States and China. The Act introduces fast‑track regulatory pathways, a strategic‑project framework...
Re: England Athletics Promotion of Medical Knee Procedure to Runners on Eve of London Marathon Is Condemned by Experts
England Athletics recently promoted Arthrosamid, a Class IIb implantable knee device, to runners ahead of the London Marathon. The product, marketed as a "drug," bypasses many safety tests because it carries a CE mark that allows manufacturer self‑certification. A UK...
Care Coordination Trumps Workflow Efficiency for Better Outcomes
Strong SNF workflows matter. But care coordination matters even more. Shweta Shanbhag from PointClickCare explains why improving post-acute outcomes requires both workflow efficiency and cross-continuum collaboration. 🔗 https://t.co/AmjfZ0G5Ii @PointClickCare #VBC #HITSM https://t.co/y5OPrxUfvB
Beyond the Scale: How Imaging Can Help Determine GLP-1 Efficacy
The GLP‑1 drug class now reaches roughly 12% of U.S. adults, making it one of the fastest‑adopted therapies in recent history. Critics argue that weight alone is an inadequate measure of success, prompting Hone Health to partner with imaging startup...
FDA Awards Three Priority Review Vouchers For Psychedelics
On April 24, 2026 the FDA announced it will issue three priority review vouchers to companies developing psychedelic therapies. The vouchers cover two psilocybin programs targeting treatment‑resistant and major depressive disorder, and a methylone program for post‑traumatic stress disorder. The...
Hair Loss in Women ‘Increasingly Mentioned’
Hair loss in women is becoming a more frequent concern, with the Cleveland Clinic estimating that 30 million U.S. women are affected and more than half will notice visible thinning. At the ACP Internal Medicine Meeting, dermatologist Dr. Ashley Wentworth highlighted...
Ontario Hospitals Announce Job Cuts, Nearly Three-Quarters of Hospitals in Deficit
Ontario hospitals are slashing jobs as financial deficits widen, with more than 70% of facilities forecasting shortfalls. A $1.1 billion CAD ($800 million USD) provincial boost proved insufficient, prompting The Ottawa Hospital to cut about 3% of its workforce through early retirements...
Stocks, Sentiment, GLP‑1 Coverage, and Chicken’s Protein Surge
🆓 Friday links: stocks vs. consumer sentiment, changing GLP-1 insurance coverage, and why chicken is winning the protein wars. https://t.co/GDZOuIDdXc image: https://t.co/FMxRMKtvwl https://t.co/gkbVYNPUru
Eliminating Patient Hold Times: Catholic Health’s Rapid Deployment of Voice AI
Catholic Health tackled low MyChart adoption and costly call‑center inefficiencies by deploying Notable’s voice AI in its Help Desk. The AI agents lifted call containment from a 30% target to 64%, cutting monthly call costs by $60,000 and projecting $360,000...
AI Heralds a Golden Era in Medicine
Are we entering a “golden era” of medicine? ☀️ Dr. Ruben Amarasingham explains how AI is transforming everything from clinical notes to revenue cycle management. 👇 https://t.co/Kx90jn9qlj #SmarterTechnologies #ViVE2026 #HITSM
FDA Unveils Three Psychedelic-Focused Commissioner Vouchers
The U.S. Food and Drug Administration announced it has issued fast‑track “commissioner vouchers” to three psychedelic‑focused companies. The agency withheld the identities of the sponsors, a move that surprised investors and analysts. The vouchers are designed to expedite regulatory review,...
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
The U.S. Food and Drug Administration issued a complete response letter to AbbVie, rejecting its biologics license application for trenibotulinumtoxinE due to manufacturing and CMC deficiencies. The setback delays AbbVie’s entry into the lucrative neurotoxin market, a segment dominated by...
Why Your Tortillas Now Have Folic Acid (And Why That Matters for Latina Health)
On Jan 1 2026 California enacted a law requiring folic acid fortification of all commercially produced corn masa products, including tortillas. The measure targets the higher incidence of neural‑tube defects among Latina births, a gap left by earlier grain‑fortification policies that excluded...
AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
Isomorphic Labs, the DeepMind spinoff behind AlphaFold, announced that its AI‑designed drug candidates will soon enter human clinical trials. The company’s new IsoDDE engine claims to double the accuracy of AlphaFold 3 in predicting protein‑small‑molecule interactions. Partnerships with Eli Lilly and Novartis...
BROKE: Mills Quietly Freezes MaineCare Provider Payments Until July 1 as Fraud Probes Close In
Governor Janet Mills’ Department of Health and Human Services has again frozen MaineCare provider payments, postponing pharmacy claims from mid‑May through June 30 until the start of the new fiscal year on July 1. The delay follows a supplemental budget that...
Eugene Braunwald: Repeatedly Revolutionizing Cardiology
On the passing of Dr. Braunwald... 🩺How Dr. Eugene Braunwald changed cardiology, again and again and again. https://t.co/IaAIMy3X3N #medicine #cardiology @harvardmed @CMichaelGibson
Brooks-TLC Workers Ratify Contract Extension
Members of 1199SEIU United Healthcare Workers East at Brooks‑TLC Hospital System ratified a one‑year contract extension covering more than 160 employees. The agreement, effective until April 30, 2027, delivers a 3.75% wage increase and targeted hourly bumps for surgical technicians,...
Vanderbilt Chief Heads to Dana-Farber
Vanderbilt Health’s system surgeon‑in‑chief Seth Karp will leave on Oct. 15 to become surgeon‑in‑chief at Boston’s Dana‑Farber Cancer Institute. He will simultaneously chair the Department of Surgery at Beth Israel Deaconess Medical Center. The move coincides with Dana‑Farber’s $1.68 billion partnership with...
Washington Hospital Restructures Clinic, Ends Pain Management Services
East Adams Rural Healthcare (EARH) in Ritzville, Washington, is resetting its rural health clinic after a near‑closure caused by financial strain. The new model, effective June 1, will staff the clinic with a single provider on‑site each day, supported by a...
The Quiet Gaps in ED Performance Data — and What Execs Can Do About Them
Hospital leaders now have unprecedented access to emergency department (ED) data, but without adjusting for patient acuity and using appropriate peer groups, the information can be misleading. The CDC’s federal ED utilization report ended in 2022, leaving a fragmented landscape...
Top Strategies Driving Success in Healthcare Search
What’s actually working in healthcare search right now? We break it down with Lacey Reichwald. 👉 Hear the full interview: https://t.co/ySBa6IYcvJ @ahamediagroup #marketingstrategy #hcmktg
Birthday Cards Are Just the Start: Inside AdventHealth’s Hospitality Strategy
AdventHealth launched its Health Parks—a 36,000‑square‑foot, one‑stop‑shop model that bundles lab, imaging, primary care and specialty services under a single roof. The integrated layout lets 1‑2 of every 3 patients receive multiple services in one visit, reducing the need for...
Designer Baby Companies Are in Turmoil
Two high‑profile germline‑editing startups—Bootstrap Bio and Manhattan Genomics—have ceased operations within a year of launching. Bootstrap Bio folded after running out of capital and was further tarnished by the federal arrest of its chief science officer on child‑sex‑trafficking charges. Manhattan...
No Benefit, Maybe Harm, With Invasive Approach in Frail NSTEMI Patients
Analysis of the SENIOR‑RITA trial’s frailty sub‑study shows that severely frail NSTEMI patients do not benefit from routine invasive angiography and revascularization. Over a median 4.1‑year follow‑up, the composite of cardiovascular death or non‑fatal MI occurred in 37.7% of frail...
Friday Subscriber Discussion - Action!
The Friday Subscriber Discussion post invites readers to brainstorm actionable steps for reducing institutional weight stigma. It highlights everyday barriers, such as non‑armless chairs in waiting rooms, and encourages community members to share practical suggestions. The author frames the conversation...
Building a Better Delivery System for Gene Editing Machines by Re-Engineering the Cellular Factory
A genome‑wide knockout screen conducted by the Whitehead Institute revealed specific producer‑cell genes that govern the assembly and potency of virus‑like particles (VLPs) used for gene‑editing delivery. Disabling a single brake gene dramatically increased guide‑RNA loading, boosting particle potency across...
Biopharma Money Raised: Jan. 1-April 23, 2026
Regeneron’s Otarmeni, a gene‑therapy for congenital hearing loss, earned FDA accelerated approval and will be provided free of charge, marking a rare zero‑cost gene‑therapy launch. At AACR 2026, researchers highlighted breakthroughs in minimal residual disease (MRD) detection that sharpen relapse...
Many High-Risk Pregnant Patients Still Miss Out on Guideline-Recommended Care
New research from the Mass General Brigham system reveals that only about a quarter of high‑risk pregnant patients receive the guideline‑recommended low‑dose aspirin to prevent preeclampsia. The study, covering more than 60,000 pregnancies from 2013 to 2023, shows aspirin use...